The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models.
Matthew John Barth
No relevant relationships to disclose
Gopichand Pendurti
No relevant relationships to disclose
Cory Mavis
No relevant relationships to disclose
Natalie Czuczman
No relevant relationships to disclose
Jospeh J. Skitzki
No relevant relationships to disclose
Francisco J. Hernandez-Ilizaliturri
No relevant relationships to disclose
Myron Stefan Czuczman
Research Funding - Genmab